Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer

Abstract

Tabulated below are “targeted” or novel agents that are being or have been evaluated in non-small cell lung cancer (NSCLC) and small cell lung cancer. Only compounds that have entered clinical trials have been listed. The compounds are listed by class, and under each class, they are listed in the order of their phase of clinical development, with those in the latest phase being listed first. The phase of development in lung cancer is also noted if it differs from the latest phase of development in other malignancies. The classes are listed alphabetically, except for the first two categories (epidermal growth factor receptor and vascular endothelial growth factor receptor inhibitors) because drugs from this category are approved for NSCLC and are in common clinical practice. Drugs that do not fall into specific broad categories are clumped under “others” at the end of the Table 1. We have made every attempt to be current and comprehensive, and this table is essentially designed to be a quick reference tool; however, the information listed is dynamic and constantly evolving, and therefore, the reader is encouraged to look for further updates that may have been reported after the publication of this table. This is especially pertinent for compounds currently undergoing phase III testing. In the last column, the list of toxicities is given. This list is not intended to be comprehensive, but only the prototypic or most commonly seen “class effect” toxicities are noted. The toxicity column has been left blank for compounds very early in development for which mature toxicity data are not available. The phase of the trial is also listed in the last but one column. If the phase of development in lung cancer differs from the overall development of the agent, then this has been explicitly stated. Compounds still in phase I development has been also listed. Nevertheless, only those compounds of potential utility for lung cancer and that are also enrolling patients with lung cancer are listed. If a compound is undergoing lung cancer-specific phase I testing, then this has also been stated. When available, the generic name, trade name(s), and other accepted name(s) or phrase(s) used to refer an agent have also been listed. A blank space indicates that a generic or trade name did not exist at the time of writing. Nevertheless, this might have changed by the time this article is published. *Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and †Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina. Disclosure: The authors declare no conflicts of interest. Address for correspondence: George R. Simon, MD, Hematology/Oncology Division, 96 Jonathan Lucas Street, Suite 903, MSC 635, Medical University of South Carolina, Charleston, SC 29425. E-mail: simong@musc.edu Copyright © 2010 by the International Association for the Study of Lung Cancer. ISSN: 1556-0864/10/0512-0433 Santa Monica Supplement Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 6, December 2010